The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving ...

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. PHILADELPHIA--(BUSINESS WIRE)-- ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a 200 mg Benlysta autoinjector for children aged 5 years and ...

The U.S. Food and Drug Administration has approved GlaxoSmithKline's 200-mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and older with active systemic ...

In addition to reducing lupus flare risk and frequency, the drug Benlysta® can also minimize healthcare costs, according to a new study. Benlysta is a prescription medication to treat lupus and lupus ...

Benlysta®: What You Need to Know There are different medications available for treating lupus. One option is Benlysta® (belimumab). Below are answers to some of the questions you may have about this ...

Benlysta is now the first and only biologic approved for adults and children who have lupus or lupus nephritis Please see US Prescribing Information for Benlysta. This is the first FDA-approved ...

If you can become pregnant, it’s important to consider whether Benlysta is a safe choice for you. Monoclonal antibodies, such as belimumab (the active drug in Benlysta), may affect the immune system ...

GlaxoSmithKline's Benlysta has long enjoyed its place as the sole biologic approved to treat lupus, despite other drugmakers' forays into the field. But with competitors sniffing around, GSK is ...

The approval makes belimumab (Benlysta) the first at-home treatment in its class for patients 5 years and older with systemic lupus erythematosus (SLE). The FDA approved GSK’s belimumab (Benlysta) ...

LONDON-- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with ...